4/16
03:11 am
traw
Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ... [Yahoo! Finance]
Low
Report
Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ... [Yahoo! Finance]
4/16
12:43 am
traw
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Traws Pharma, Inc. (TRAW) Q4 2025 Earnings Call Transcript [Seeking Alpha]
4/15
08:12 pm
traw
Traws Pharma Announces Up to $60 Million Private Placement Financing [Yahoo! Finance]
Low
Report
Traws Pharma Announces Up to $60 Million Private Placement Financing [Yahoo! Finance]
4/15
04:01 pm
traw
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Medium
Report
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
4/15
08:15 am
traw
Traws Pharma Announces Up to $60 Million Private Placement Financing
High
Report
Traws Pharma Announces Up to $60 Million Private Placement Financing
2/19
07:30 am
traw
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
High
Report
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
1/31
07:46 am
traw
Traws Pharma (NASDAQ:TRAW) was upgraded by analysts at LADENBURG THALM/SH SH to a "strong-buy" rating.
Medium
Report
Traws Pharma (NASDAQ:TRAW) was upgraded by analysts at LADENBURG THALM/SH SH to a "strong-buy" rating.
1/26
08:42 am
traw
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza [Yahoo! Finance]
Medium
Report
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza [Yahoo! Finance]
1/26
08:30 am
traw
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
High
Report
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza